Galera Makes Key Personnel Changes

Galera Therapeutics

MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) announced the recent appointment of Mark J. Bachleda, Pharm.D., M.B.A., as Chief Commercial Officer (CCO) and Jennifer Evans Stacey, Esq., as Chief Legal and Compliance Officer (CLCO) and Secretary. Both executives join Galera with over 25 years of leadership experience within the biopharmaceutical industry.

“We are thrilled to welcome Mark and Jennifer to Galera at this critical point in the Company’s growth,” said Mel Sorensen, M.D., Galera’s President and CEO. “As we begin to expand our focus toward becoming a commercial-stage company, we will leverage our two new colleagues’ executive-level experiences to continue shaping Galera’s corporate and regulatory strategy. We look forward to their invaluable contributions that will help position us to achieve our mission of delivering novel therapies that improve outcomes for patients with cancer undergoing radiotherapy.”

Prior to joining Galera, Mark served as Vice President & U.S. Business Unit Head for Bristol Myers Squibb’s (BMS) CAR T cell therapy franchise. At BMS, he was responsible for building core U.S. commercial capabilities and the successful launch execution of Breyanzi® and Abecma®. Prior to BMS, Mark was Vice President of Sales at Juno Therapeutics, a biotechnology company acquired by Celgene in 2018. Prior to Juno, Mark worked at Amgen for 15 years in a variety of U.S. and international commercial operations roles. His most recent role was General Manager of Amgen Czech Republic, where he led an enterprise of 11 commercialized therapies including launches of Kyprolis®, Blincyto®, and Repatha®. Mark is a registered pharmacist and received his Pharm.D. degree from the University of Illinois at Chicago. He completed a post-doctoral fellowship in health policy and economics at Thomas Jefferson University and earned M.B.A. degrees from both Columbia University and the University of California, Berkeley.

READ:  Radian Honored as a “Champion of Board Diversity” by Forum of Executive Women

“I am delighted to join Galera as the Company prepares for potential commercialization of its lead asset, avasopasem,” commented Mark J. Bachleda, Pharm.D., M.B.A. “In only a few years, the Company has advanced avasopasem into a pivotal Phase 3 trial, which has the potential to become the new standard of care for severe oral mucositis in patients with head and neck cancer. I am eager to collaborate with the Galera management team as we dedicate our efforts to bringing this therapy to market and making it available for cancer patients in need.”

Previously, Jennifer served as Vice President, General Counsel, Secretary and Government Relations at The Wistar Institute, an independent international biomedical research institution. During her tenure, she drafted and negotiated license and equity agreements to launch six start-ups that helped advance Wistar technology. Prior to her role at Wistar, Jennifer was the Senior Vice President, General Counsel, Human Resources and Secretary for Antares Pharma, a publicly traded pharmaceuticals company. Before that, Jennifer was Executive Vice President, General Counsel, Human Resources and Secretary for Auxilium Pharmaceuticals, Inc., a publicly traded biopharmaceutical company acquired by Endo International plc. Jennifer earned her J.D. from the University of Pennsylvania Law School and her A.B. from Princeton University.

READ:  Family Law and Criminal Defense Attorney Kelly A. Jurs Joins Gawthrop Greenwood, PC

“I am excited to partner with Galera’s driven and dynamic management team to help advance the Company’s novel dismutase mimetic product candidates through late-stage development,” said Jennifer Evans Stacey, Esq. “Galera’s assets have the potential to significantly improve quality of life for patients. I look forward to leading the Company’s legal, compliance and human resources divisions during this significant time.”

Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.